Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$4.82 +22.32%

+$0.85 today

Market cap
$58.59M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.03M

Average 0.01M

NTRB Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Nutriband Inc.NASDAQ: NTRB

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Apr 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 12.16M shares rose 9.3% year over year, ahead of the +8.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +11.2% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.3% holds above the trailing-twelve-month pace of +8.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
12.16M+0.0% QoQ
Last fiscal yearJan 2026
11.64M+9.7% YoY
LTMApr 2026
11.9M+8.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.3%——
1 year+9.7%——
3-year CAGR+11.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
11.64M USD
Year-over-year change
+9.7%
4-year CAGR
+10.1%

Weighted Avg Shares (Diluted) vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 weighted avg shares (diluted) of 11.9M shares is the 8th highest of the 9 companies compared; the peer median is 36.9M shares.
  • Its year-over-year change of +8.4% is the 5th highest of 8, against a peer median of +28.8%.
  • Over three fiscal years its annual growth of +11.2% compares with a peer median of +29.8%.
NTRB Competitors Peer median
Weighted Avg Shares (Diluted) for NTRB and competitors
Company Period LTM YoY 3-year CAGR
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
FBIOFortress Biotech, Inc.LTM Mar 202695.09M +349.0%+261.1%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
ADAGAdagene Inc.LTM Jun 202435.23M —+2.9%
GANXGain Therapeutics, Inc.LTM Mar 202635.13M +38.4%+40.5%
XBITXBiotech Inc.LTM Mar 202630.49M +0.1%+0.1%
NTRBNutriband Inc.LTM Apr 202611.9M +8.4%+11.2%
ACETAdicet Bio, Inc.LTM Mar 20267.26M +28.8%+39.0%
Peer median (excluding NTRB) 36.9M+28.8%+29.8%

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.42M2.08M2.09M2.14M2.04M
Cost of Revenue917.84K1.33M1.22M1.44M1.47M
Gross Profit504.31K750.41K862.11K699.3K566.31K
Gross Margin35.5%36.1%41.3%32.7%27.8%
Research & Development411.38K982.23K1.96M3.12M1.89M
Selling, General & Admin4.02M3.92M3.77M4.27M6.99M
Operating Expenses4.43M4.9M5.73M7.39M8.88M
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
EBITDA(5.74M)(4.11M)(5.12M)(10.18M)(8.01M)
EBITDA Margin-403.6%-197.5%-245.6%-475.5%-393.5%
Operating Income(3.93M)(4.15M)(4.87M)(6.69M)(8.32M)
Operating Margin-276.3%-199.5%-233.6%-312.6%-408.4%
Interest Income0016.85K191.67K0
Interest Expense118.42K8.29K75.82K21.41K22.54K
Other Income / Expenses(2.25M)(335.62K)(613.39K)(3.79M)88.33K
Income Before Tax(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Pre-Tax Margin-434.3%-215.6%-263.0%-489.9%-404.1%
Income Tax Expense00000
Net Income(8.42M)(4.81M)(5.49M)(10.48M)(8.23M)
Net Margin-592.2%-231.3%-263.0%-489.9%-404.1%
EPS (Basic)(1.06)(0.57)(0.69)(0.99)(2.58)
EPS (Diluted)(1.06)(0.57)(0.69)(0.99)(2.58)
Weighted Avg Shares7.93M8.46M7.95M10.61M11.64M
Weighted Avg Shares (Diluted)7.93M8.46M7.95M10.61M11.64M

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$4.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.